Costimulatory bispecifics bring new biology to T cell engagers BY LAUREN MARTZ, EXECUTIVE DIRECTOR, BIOPHARMA INTELLIGENCE Two T cell engaging bispecific antibodies may be better than one when it comes to driving activation of T cells against tumors, according...
News
EvolveImmune Therapeutics to Present New Preclinical and Translational Data Highlighting Precision Medicine Potential of its Novel Costimulatory T Cell Engager Platform at 38th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)
EvolveImmune Therapeutics to Present New Preclinical and Translational Data Highlighting Precision Medicine Potential of its Novel Costimulatory T Cell Engager Platform at 38th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) EVOLVE Platform...
EvolveImmune Therapeutics Enters into Strategic Research Collaboration with Kennedy Institute of Rheumatology
Collaboration with Researchers at University of Oxford to Utilize State-of-the-Art Technology to Characterize Immune Synapse Formation Mediated by First-In-Category EVOLVE Molecules BRANFORD, CT – June 14, 2023 – EvolveImmune Therapeutics, an immuno-oncology company...
EvolveImmune Therapeutics Reports First Results from CRISPR-Cas9 T Cell Exhaustion Screening Platform at American Association for Cancer Research (AACR) Annual Meeting 2023
EvolveImmune Therapeutics Reports First Results from CRISPR-Cas9 T Cell Exhaustion Screening Platform at American Association for Cancer Research (AACR) Annual Meeting 2023 Novel Technology Identified Genes that Promote T Cell Exhaustion, and which are Unique...
EvolveImmune Therapeutics Presents New Preclinical Data Demonstrating Improved Anti-Tumor Potential of Novel Costimulatory T Cell Engager Platform at Festival of Biologics Immunotherapy World Congress
EvolveImmune Therapeutics Presents New Preclinical Data Demonstrating Improved Anti-Tumor Potential of Novel Costimulatory T Cell Engager Platform at Festival of Biologics Immunotherapy World Congress Company Unveils EVOLVE-105 Program, A Best-in-Class...
EvolveImmune Therapeutics Reports Preclinical Data Highlighting Deep and Durable Anti-Tumor Efficacy with EV-104 in Presentation at 37th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) – SITC Poster available through this link
Poster Spotlights CD2 Pathway as a Differentiated T Cell Costimulation Approach for the Treatment of Solid and Hematological Malignancies Modular Platform Being Leveraged to Advance Broad Pipeline of First-in-Category Costimulatory T Cell Engager Immunotherapies...
EvolveImmune Therapeutics Presents Promising Preclinical Data from Novel Costimulatory T Cell Engager Platform at American Association for Cancer Research (AACR) Special Conference on Tumor Immunology and Immunotherapy
EVOLVE™ Platform Shows Promise as a Differentiated T Cell Costimulation Approach for the Treatment of Solid and Hematological Malignancies Presentation Highlights CD2 as an Optimal Costimulatory Target; Demonstrates Durable in vivo Anti-Tumor Efficacy with EVOLVE ...
EvolveImmune Therapeutics to Present New Preclinical Data from Novel Costimulatory T Cell Engager Platform at Upcoming Scientific Conferences
EVOLVE™ Platform Shows Promise as a Differentiated T Cell Costimulation Approach for the Treatment of Solid and Hematological Malignancies Poster Presentations Scheduled for American Association for Cancer Research (AACR) Special Conference on Tumor Immunology and...
EvolveImmune Therapeutics Appoints Jay Fine, Ph.D., as President of Research and Development
Over 30 Years of Leadership in Drug Discovery and Development, Translational Sciences and Biomarker Research in Immunology, Inflammatory Diseases and Tissue Fibrosis in Biopharma BRANFORD, CT – July 7, 2022 – EvolveImmune Therapeutics, an immuno-oncology company...
EvolveImmune Therapeutics Welcomes Ian Taylor, PhD to the Board of Directors
BRANFORD, CONN., April 29, 2021 — EvolveImmune Therapeutics, Inc., an emerging, privately held immunotherapy platform company, is pleased to announce that Ian Taylor, PhD has joined its board of directors. Dr. Taylor is a veteran biopharma executive who brings...
Industry vets launch biotech in Branford targeting cancer, autoimmune disease
New Haven Biz highlighted the opening of EvolveImmune’s new headquarters in Branford, CT. Fully story at New Haven Biz.
EvolveImmune celebrates opening of state-of-the-art lab and office complex in Branford, Connecticut
Community leaders and team members gathered on October 22 to celebrate the opening of EvolveImmune’s new 9,000 square foot lab and office complex located in the Business Park Drive biotech cluster. Stephen Bloch, MD, Co-Founder and CEO made remarks along with the...